Inspired by the anti-AChE activity of 22, and from the observation that the 2-aminoimidazole group in this compound is also found in the known β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitors, Vitale et al. have searched for molecules that share a similar scaffold as potential multi-targeted compounds for AD therapy. The gene discussed is ACHE; the disease is Alzheimer disease.